8:00 am Chair’s Opening Remarks

Lessons Learned from the Three Commercially Approved ADCs in 2019

8:10 am Polatuzumab Vedotin From Beginning to Approval & Beyond


• Reviewing the discovery of Polatuzumab
• Evaluating early clinical data and gaining approval
• Exploring future combinations

8:40 am PADCEV: An Evolution in the Therapeutic Landscape of Urothelial Cancer

  • Daejin Abidoje Vice President, Clinical Development , Seattle Genetics


• Assessing ADCs as a new therapeutic class in bladder cancer and PADCEV’s unique mechanism of action
• Analyzing data on efficacy/safety of PADCEV in metastatic urothelial cancer and ongoing exploration of its activity in early bladder cancer
• Evaluating PADCEV as an MMAE-class ADC and its potential synergy with immunotherapy

9:10 am The Development & Approval of Enhertu in Patients with Unresectable or Metastatic HER2-positive Breast Cancer

  • Gilles Gallant Senior Vice President, Global Head, Oncology Development, Daiichi Sankyo


• Outlining the pre-clinical profile and mechanism of action of Enhertu ([Fam-] trastuzumab deruxtecan, DS-8201a, T-DXd)
• Reviewing clinical development leading to the approval of Enhertu
• Understanding the current development status of Enhertu

9:40 am
Speed Networking


This session is a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with. Get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business relationships.

10:30 am
Morning Refreshments

11:00 am

12:30 pm
Lunch & Networking – Sartorius Lunch Seminar

  • Ian Schwartz Global Bioconjugation Technology Consultant, Sartorius Stedium Biotech

1:15 pm

3:45 pm
Afternoon Refreshments & Networking

Looking at Future Approvals & Current Pioneering Scientific Developments

4:15 pm An Overview of the Successful Development of Loncastuximab tesirine, a PBD Based ADC Directed Against CD19 for the Treatment of Hematological Malignancies


• Review the preclinical data for IND approval
• Gain an overview of manufacturing strategy
• Analyze the clinical data

4:45 pm “Light Path” – Leveraging Lonza’s Experience with Timelines & Cost Reduction of Bioconjugate Drug Substance Supply


• Discover Lonza’s ADC capabilities and learn about future capacity increases at the manufacturing site in Switzerland
• Roll-out of a novel ADC manufacturing offer/concept for customers: BioConjugates LightPath Development
• Fast generation of ADC drug substance to support clinical phase I trials; Utilize Lonza’s bioconjugation experience to reduce customer effort to a minimum and accelerate project timelines

5:15 pm Antibody Targeted Amanitin Conjugates (ATAC)

  • Andreas Pahl Chief Scientific Officer & Executive Vice President & Member of the Executive Board, Heidelberg Pharma


• Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin
• Understand how this payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II
• Learn more about this technology platform that includes Amanitin supply, site specific conjugation, demonstrated safety profile and biomarker
• Gain insights into HDP-101;The first ATAC directed against BCMA entering Phase I trials in 2020

5:45 pm Chair’s Closing Remarks

5:50 pm
Scientific Poster Session & Drinks Reception


The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session over 60 scientific posters will be presented from novel linker designs to validation of site-specific conjugation technologies and more informative in vivo models.